NLRP3 and metabolic dysfunction-associated steatohepatitis: Specifically, they have shown that in NASH livers, macrophage Nrf2 regulates ROS-mediated stabilization of YAP, which in turn inhibits NLRP3 inflammasome activation, leading to amelioration of steatohepatitis symptoms.